No Data
Qingdao Baheal Medical INC.: 2025 First Quarter Report
Qingdao Baheal Medical INC.: Summary of the 2024 Annual Report
Qingdao Baheal Medical INC.: 2024 Annual Report
Baiyang Pharmaceutical (301015.SZ): Net income of 0.692 billion yuan in 2024, a year-on-year decrease of 2.87%.
On April 23, Gelonghui reported that Baiyang Pharmaceutical (301015.SZ) released its annual report for 2024, with revenue of 8.094 billion yuan, a year-on-year decrease of 1.96%. The Net income attributable to the shareholders of the listed company was 0.692 billion yuan, a year-on-year decrease of 2.87%. The EPS was 1.32 yuan. In addition, it is proposed to distribute a cash dividend of 7.62 yuan (including tax) for every 10 shares to all shareholders.
Baiyang Pharmaceuticals (301015.SZ) announced its 2024 annual performance, with a net income of 0.692 billion yuan, a decrease of 2.87%.
Baiyang Pharmaceutical (301015.SZ) released its annual report for 2024, with the company's revenue at 8.094 billion...
Baiyang Pharmaceutical (301015.SZ): The products imported from the USA have a very low impact on the company's gross profit and are affected less.
On April 10, Gelonghui reported that Baiyang Pharmaceutical (301015.SZ) stated on the investor interaction platform that in recent years, the company’s upstream customers in the USA have established a global production supply chain, and the products imported from the USA have a minimal impact on the company's gross profit, being largely unaffected. The company will closely monitor changes and developments in international trade policies and continue to reduce potential risks through diversification and supply chain optimization.
Shareholders Are Optimistic That Qingdao Baheal Medical (SZSE:301015) Will Multiply In Value
